Rifampicin-Induced Pulmonary Embolism: A Rare Side Effect

Alawad, Mouhammad J; Albuni, Mhd Kutaiba; Subahi, Eihab A; Kamal, Ijaz

doi:10.7759/cureus.18904

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S-a postulat, că este un process multifactorial, iar ca mecanisme posibile pot fi: dereglarea metabolismului proteinelor procoagulante și anticoa-gulante; dezvoltarea unui mecanism immunologic. Astfel, la prescrierea ansamicinelor e necesară o analiză minuțiosă a istoricului pacienților cu determinarea parametrilor specifici și monitorizarea coagulabilității, îndeosebi la prezența factorilor de risc [1,3].…”

Section: Rezultate Și Discuțiiunclassified

“…Starea de hipercoagulabilitate se consideră rezultatul inflamației cronice cu creșterea nivelului factorului VIII, fibrinogenului și inhibitorului activatorului plasminogenului, precum și reducerea proteinei C și antitrombinei III. Tuberculoza activă se poate complica cu tromboembolism venos (TEV) datorită inflamației cronice, stării de hipercoagulare sau leziunii endoteliale directe [1,7].…”

Section: Introducereunclassified

See 1 more Smart Citation

Adverse hematological and coagulability reactions to the use of antituberculosis preparations

Bacinschi,

Donica,

Tudor

2024

BulMed

View full text Add to dashboard Cite

Treatment of tuberculosis requires long-term use of antituberculosis drugs with a high risk of side effects. In recent decades, along with the frequent and detailed side effects (gastrointestinal symptoms, hepatotoxicity, neurotoxicity, allergic reactions), hematological and coagulation disorders have been described when taking antituberculosis drugs. Their main manifestations can be: iron deficiency anemia, hemolytic anemia, megaloblastic and sideroblastic anemia, thrombocytopenia, thrombocytopenic purpura, leukopenia, eosinophilia, agranulocytosis, deep vein thrombosis, thromboembolism, disseminated intravenous coagulopathy, etc. Although these side effects are rare, they require special attention because they can appear more frequently in the case of intermittent or interrupted treatment and present diagnostic difficulties.

show abstract

Section: Rezultate Și Discuțiiunclassified

Section: Introducereunclassified

Adverse hematological and coagulability reactions to the use of antituberculosis preparations

Bacinschi,

Donica,

Tudor

2024

BulMed

View full text Add to dashboard Cite

show abstract

Venous thromboemboliс complications and tuberculosis: is there an interaction?

Plotkin,

Titomer,

Reshetnikov

et al. 2023

jour

View full text Add to dashboard Cite

Venous thromboembolic complications (VTEC) haven’t lost their status as an important medical and social problem for many decades. There are about 300 thousand people die from VTEC in Russia every year. Another significant problem for our country is tuberculosis. Tuberculosis is one of the most common severe infections in the world, most often occurs as a chronic disease and can induce VTEC due to a variety of synergistically acting factors. Previously published studies examined the interaction between tuberculosis and VTEC, but they were based on the data obtained from countries with a high incidence of tuberculosis and a low prevalence of venous thrombosis. An analysis of the literature has shown that tuberculous inflammation determines all three interrelated components of the Virchow’s triad: endothelium inflammatory damage, venous stasis and hypercoagulability. In addition, treatment regimens for the disease with the inclusion of rifampicin also contribute to the development of VTEC due to the pronounced procoagulant properties of the drug. Another equally important agent that potentiates hypercoagulation is the HIV virus, which affects the endothelium and immunocompetent cells. Currently available epidemiological data indicate that HIV infection is associated with an increased risk of VTEC in 2-10 times compared to the general population of the same age. In this context, tuberculosis and HIV/TB co-infection can be considered as a large reversible risk factor for the development of VTEC and included in the prognostic risk assessment scales for acute venous thrombosis and embolism.

show abstract

Rifampicin-Induced Pulmonary Embolism: A Rare Side Effect

Cited by 2 publications

References 9 publications

Adverse hematological and coagulability reactions to the use of antituberculosis preparations

Adverse hematological and coagulability reactions to the use of antituberculosis preparations

Venous thromboemboliс complications and tuberculosis: is there an interaction?

Contact Info

Product

Resources

About